Ozempic is not approved for type 1 diabetes. The FDA specifically states that Ozempic “is not indicated for use in patients with type 1 diabetes mellitus.” It is approved only for type 2 diabetes. However, a growing number of doctors are prescribing it off-label to people with type 1 diabetes, particularly those who also have obesity, and early clinical trial results suggest real benefits alongside real risks.
Why Ozempic Wasn’t Designed for Type 1
Type 1 diabetes is an autoimmune condition where the pancreas produces little or no insulin. Ozempic (semaglutide) works partly by stimulating the pancreas to release more insulin when blood sugar rises. In someone with type 1, that mechanism is largely irrelevant because the insulin-producing cells are already destroyed. This is the core reason the drug was developed and tested for type 2 diabetes, where the pancreas still functions but the body responds poorly to the insulin it makes.
That said, semaglutide does other things beyond boosting insulin production, and those secondary effects turn out to matter for type 1 as well.
How It Can Still Help in Type 1
People with type 1 diabetes often have abnormally high levels of glucagon, a hormone that tells the liver to dump glucose into the bloodstream. Without enough insulin to counterbalance it, this excess glucagon drives blood sugar higher. Semaglutide suppresses glucagon release from the pancreas, which reduces the liver’s glucose output and helps stabilize blood sugar levels.
The drug also slows stomach emptying, which means food is absorbed more gradually after meals. For people with type 1, this reduces the sharp post-meal blood sugar spikes that are notoriously difficult to manage, even with well-timed insulin doses. These two mechanisms, glucagon suppression and slower digestion, are the main reasons researchers have been studying semaglutide in type 1 populations.
What Clinical Trials Show
The most notable recent trial, called ADJUST-T1D, studied adults with type 1 diabetes and obesity who were using automated insulin delivery systems (insulin pumps with continuous glucose monitors). Over 26 weeks, participants taking semaglutide saw a 22.6% reduction in their total daily insulin dose. That broke down to a 30.5% drop in mealtime (bolus) insulin and a 15.6% drop in background (basal) insulin. Their average A1C dropped by an additional 0.3% compared to placebo.
Weight loss was substantial. Participants on semaglutide lost an average of about 18.5 pounds over six months. In a separate analysis, 36% of those taking semaglutide hit all three key health targets: improved blood glucose, less time in low blood sugar, and at least 5% body weight loss. None of the participants on placebo achieved all three.
Larger trials with liraglutide, a related drug in the same class, showed similar patterns: roughly 0.4% A1C reduction, about 11 pounds of weight loss, and meaningful decreases in insulin requirements.
The Risks Are Serious
The biggest danger when combining semaglutide with insulin in type 1 diabetes is diabetic ketoacidosis (DKA). This life-threatening condition occurs when the body doesn’t have enough insulin and starts breaking down fat for fuel, producing dangerous levels of ketones in the blood. When people start a GLP-1 drug like semaglutide and reduce their insulin too quickly, or stop it altogether, DKA can develop within days.
Reports from the UK’s drug safety monitoring system found that roughly a third of DKA cases linked to GLP-1 drugs occurred when insulin was either discontinued or reduced too rapidly at the start of treatment. Many of these cases happened within the first two weeks. For someone with type 1 diabetes, who is completely dependent on external insulin, cutting back too aggressively is especially dangerous.
Hypoglycemia (dangerously low blood sugar) is the other major concern. Because semaglutide lowers blood sugar through multiple pathways, the usual insulin doses can become too strong. Researchers involved in the ADJUST-T1D trial suggest that reducing insulin doses by about 20% when starting semaglutide is a reasonable starting point to minimize this risk.
Who Is Actually Using It
Prescriptions for GLP-1 drugs in the type 1 population are rising, even without formal approval. The people receiving them tend to have a specific profile. Data from prescribing patterns show that GLP-1 users with type 1 diabetes had an average BMI of 35 (well into the obesity range), compared to 27.5 in the general type 1 population. About 69% met criteria for obesity, and nearly two-thirds were women. In other words, doctors are primarily turning to these drugs when their type 1 patients also struggle significantly with weight, a combination that standard insulin therapy alone doesn’t address well.
How It Compares to SGLT2 Inhibitors
Semaglutide isn’t the only type 2 drug that has been tried in type 1. SGLT2 inhibitors, which work by causing the kidneys to excrete excess glucose in urine, were also tested. Both empagliflozin and dapagliflozin were rejected by the FDA for type 1 use because of unacceptable rates of DKA and hypoglycemia. In Europe, approvals that had been granted were later withdrawn for the same reason.
GLP-1 drugs like semaglutide appear to carry a lower DKA risk than SGLT2 inhibitors, though the concern hasn’t disappeared entirely. The weight loss and potential heart and kidney benefits seen with GLP-1 drugs in type 2 populations are a major reason interest continues in applying them to type 1, even without regulatory backing. SGLT2 inhibitor users with type 1 tended to have more kidney disease and heart complications, suggesting doctors choose between the two classes based on which additional health problems a patient has.
Where Guidelines Stand
The American Diabetes Association’s 2024 Standards of Care acknowledges the clinical trial data on GLP-1 drugs in type 1 diabetes but stops short of making a formal recommendation. The ADA notes the modest A1C reductions, weight loss, and insulin dose decreases seen in trials, and states that “the risks and benefits of adjunctive agents continue to be evaluated.” No recommendation grade has been assigned, which means using semaglutide in type 1 remains a clinical judgment call rather than a guideline-endorsed practice.
For now, any use of Ozempic in type 1 diabetes is off-label. That doesn’t mean it’s inappropriate in every case, but it does mean the prescribing doctor is working outside the drug’s tested and approved boundaries. Close monitoring of blood sugar, ketone levels, and insulin adjustments is essential, particularly in the first few weeks of treatment.